
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. has garnered positive sentiment among key opinion leaders (KOLs) in pulmonary arterial hypertension (PAH), with expectations for its product PROSERA to achieve a significant treatment effect, potentially in the range of 25 to 30 meters in the six-minute walk distance (6MWD). Despite some imperfections in the phase 2 TORREY study results, the data demonstrated consistent benefits across multiple endpoints, including pulmonary vascular resistance (PVR) reduction and pro-BNP reduction, alongside a favorable safety profile and promising durability. Increased investor interest has been noted following bullish commentary from KOLs during a recent panel discussion, indicating a rising confidence in Gossamer Bio's pipeline and market potential.
Bears say
Gossamer Bio Inc is facing a negative outlook due to the market's ongoing mispricing of seralutinib's success probabilities, which raises concerns about the validity of investor enthusiasm following a recent stock increase. The company’s clinical-stage pipeline, while focusing on critical disease areas, may not adequately offset the risks associated with the uncertainty surrounding seralutinib's chances of regulatory approval or market acceptance. Furthermore, Gossamer Bio's reliance on a few key products in its pipeline highlights potential vulnerabilities, as any setbacks in clinical trial results could significantly impact overall financial stability.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares